Lakewood-Amedex Biotherapeutics

Lakewood-Amedex Biotherapeutics Inc is a US-based company operating in Biotechnology industry. The company is headquartered in University Park, Florida and currently employs 5 full-time employees. The company went IPO on 2026-04-23. Lakewood-amedex Biotherapeutics Inc is a pharmaceutical company. The firm is focused on addressing unmet needs in the treatment of serious infectious diseases, improving patient outcomes, and significantly reducing the threat posed by antibiotic-resistant bacterial strains like MRSA, NDM-1, and many others. The firm is engaged in development of its Bisphosphocin class of antimicrobial agents. The firm is exploring additional local drug delivery applications, including complicated urinary tract infections (CAUTI) and pulmonary infections. The firm has a portfolio of compounds that are being profiled for indications such as infected diabetic foot ulcer, urinary tract infections, and pulmonary infections.